“we have very firm conviction in CARVYKTI as a $5 billion-plus asset and really are rolling that out globally very effectively at this point in time. So we don't see capacity as a constraint.”

In context

“hat there's not still a disconnect. It's just not to the extent of the others on the slide because those estimates were increased. Joe Wolk: Yeah. So just to be super clear on that one, Vamil, we are still extremely bullish based on the clinical progression, R&D, as well as the performance that we're seeing in the marketplace. I mean, look at CARVYKTI, I think, doubled sales year on year. So it's just a matter to that you guys took your numbers up and so we agree. I guess, that's maybe the best way to say that. Jennifer Taubert: And maybe just to add in a little bit more on CARVYKTI. So, yeah, over 100% operational growth in the fourth in the first quarter. In that second line plus indication. We continue to add sites. We continue to add countries. And capacity expansion globally. And so, we have very firm conviction in CARVYKTI as a $5 billion-plus asset and really are rolling that out globally very effectively at this point in time. So we don't see capacity as a constraint. Going forward based on the strength of the efforts that have taken place. And so, you know, we're full speed ahead for CARVYKTI going forward. John Reed: And with Tech and Tal, John here, you know, we're really just getting started. You've probably seen some of the recent data where we've even combined those two molecules to a really unprecedented level of complete responses. At the hematology meetings last year. We also showed combining either TEC or Tal with DARZALEX and demonstrating really impressive 100% minimal residual disease negativity in earlier lines of therapy and the opportunity therefore to really start bringing these first-in-class bispecific T cell redirecting molecules into earlier lines, even frontline in combination with our DARZALEX. So really, enormous opportunity lie”